FinTrust Capital Advisors’s Novavax NVAX Stock Holding History

FinTrust Capital Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-828	Closed	-$11K	–	1124
2020 Q1	$11K	Buy	+828	New	+$7.01K	0.01%	735

Other funds holding NVAX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

FinTrust Capital Advisors's NVAX Position: Q2 2020 in Review

FinTrust Capital Advisors sold out of Novavax (NVAX) in Q2 2020, closing a stake of 828 shares — an estimated $11K sold.

FinTrust Capital Advisors first reported a position in NVAX in Q1 2020 and held it in 1 quarter. The position peaked at $11K in Q1 2020. 213 funds tracked by Wall St. Rank hold NVAX as of Q2 2020.

FinTrust Capital Advisors reported no remaining Novavax position as of Q2 2020 after selling out during the quarter.
FinTrust Capital Advisors sold 828 Novavax shares in Q2 2020, an estimated $11K.
FinTrust Capital Advisors first reported a position in Novavax in Q1 2020 and held it in 1 quarter.
FinTrust Capital Advisors's Novavax position peaked at $11K in Q1 2020.
213 funds tracked by Wall St. Rank held Novavax as of Q2 2020.

Based on FinTrust Capital Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.